Skip to content

BioNova Receives Investigational New Drug Clearance for BN301 for the Treatment of Hematologic Malignancies in China

BioNova today announced that the Center of Drug Evaluation (CDE) of National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for BN301 (STRO-001) to conduct clinical trials in patients with hematologic malignancies in China.

Back To Top